Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987764 | 0.96 | ADORA2A (0.41) | ADORA2AHSP90AB1ADORA2BFGFR1FGFR2 | |
| SCHEMBL22988111 | 0.87 | CLK2 (0.36) | ADORA2AHSP90AB1 | |
| SCHEMBL22988153 | 0.86 | IRAK4 (0.36) | — | |
| SCHEMBL22987760 | 0.85 | CLK2 (0.34) | ADORA2A | |
| SCHEMBL22987792 | 0.85 | HSP90AB1 (0.43) | ADORA2AHSP90AB1ADORA2BFGFR1 | |
| SCHEMBL22988265 | 0.83 | CHRNB2 (0.37) | ADORA2AHSP90AB1 | |
| SCHEMBL30393332 | 0.83 | CHRNB2 (0.37) | ADORA2AHSP90AB1 | |
| SCHEMBL25118697 | 0.83 | KDM5A (0.38) | — | |
| SCHEMBL22988090 | 0.81 | HSP90AB1 (0.45) | ADORA2AHSP90AB1ADORA2B | |
| SCHEMBL22987664 | 0.80 | KDM4E (0.45) | FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA2A 103/4885HSP90AB1 2893/4885ADORA2B 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.